Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1984 1
1986 1
1988 1
1991 1
1992 1
1996 2
1997 1
1998 3
1999 3
2000 4
2001 2
2002 7
2003 12
2004 9
2005 5
2006 17
2007 30
2008 25
2009 22
2010 28
2011 23
2012 26
2013 25
2014 31
2015 22
2016 25
2017 22
2018 15
2019 15
2020 18
2021 9
2022 7
2023 8
2024 6
2025 17
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Results by year

Filters applied: . Clear all
Page 1
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA; for NRG Oncology. Brown PD, et al. J Clin Oncol. 2020 Apr 1;38(10):1019-1029. doi: 10.1200/JCO.19.02767. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058845 Free PMC article. Clinical Trial.
METHODS: This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. The primary end point was time to cognitive function failure, defined as decline using the reliable change index on at least one of the cogn …
METHODS: This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. …
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or sever …
Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Reisberg B, et al. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128. N Engl J Med. 2003. PMID: 12672860 Free article. Clinical Trial.
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. METHODS: Patients with moderate-to-sever …
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. According …
Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.
Grant JE, Chesivoir E, Valle S, Ehsan D, Chamberlain SR. Grant JE, et al. Am J Psychiatry. 2023 May 1;180(5):348-356. doi: 10.1176/appi.ajp.20220737. Epub 2023 Feb 22. Am J Psychiatry. 2023. PMID: 36856701 Clinical Trial.
In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing hair-pulling and skin-picking behavior. ...At study endpoint, 60.5% of participants in the memantine group were "much or very much imp …
In this study, the authors sought to determine whether memantine, a glutamate modulator, is more effective than placebo in reducing h …
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Dubois B, et al. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. Alzheimers Res Ther. 2023. PMID: 36849969 Free PMC article. Clinical Trial.
Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dementia due to probable Alzheimer's disease (AD). ...
Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dement …
Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder: A Randomized Clinical Trial.
Joshi G, Gönenc A, DiSalvo M, Faraone SV, Ceranoglu TA, Yule AM, Uchida M, McDougle CJ, Wozniak J. Joshi G, et al. JAMA Netw Open. 2025 Oct 1;8(10):e2534927. doi: 10.1001/jamanetworkopen.2025.34927. JAMA Netw Open. 2025. PMID: 41032298 Free PMC article. Clinical Trial.
Of these youths, 35 were included in the intention-to-treat efficacy analysis (n = 16 treated with memantine and 19 with placebo), and 33 completed the trial (n = 16 treated with memantine and 17 with placebo). ...Memantine was well tolerated and did not have …
Of these youths, 35 were included in the intention-to-treat efficacy analysis (n = 16 treated with memantine and 19 with placebo), an …
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D; Radiation Therapy Oncology Group (RTOG). Brown PD, et al. Neuro Oncol. 2013 Oct;15(10):1429-37. doi: 10.1093/neuonc/not114. Epub 2013 Aug 16. Neuro Oncol. 2013. PMID: 23956241 Free PMC article. Clinical Trial.
The memantine arm had significantly longer time to cognitive decline (hazard ratio 0.78, 95% confidence interval 0.62-0.99, P = .01); the probability of cognitive function failure at 24 weeks was 53.8% in the memantine arm and 64.9% in the placebo arm. ...Overall, p …
The memantine arm had significantly longer time to cognitive decline (hazard ratio 0.78, 95% confidence interval 0.62-0.99, P = .01); …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
CONTEXT: Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. ...All other secondary measures showed significant benefits of memantine treatment. Treatment discontinuations because of adverse events for memantine v …
CONTEXT: Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. ...All other secondary mea …
Memantine treatment improves opioid-induced hyperalgesia symptoms: randomize clinical trial.
Anjomshoaa A, Zolghadriha A, Haj-Seyed-Taghia NS, Saed O, Faghihzadeh E. Anjomshoaa A, et al. Sci Rep. 2025 Dec 15;15(1):43890. doi: 10.1038/s41598-025-23068-x. Sci Rep. 2025. PMID: 41398329 Free PMC article. Clinical Trial.

The memantine group showed significantly increased cold pain tolerance at two and four weeks post-intervention (p = 0.005 and p < 0.001) and a significant reduction in pain intensity at two week (p = 0.001), though not at four weeks (p = 0.4536). ...This study offers pr

…
The memantine group showed significantly increased cold pain tolerance at two and four weeks post-intervention (p = 0.005 and p < …
Comparative efficacy of memantine and vitamin C in postoperative pain management: a randomized clinical trial.
Saadat Fakhr M, Mohajeri A, Amini B, Shah Hosseini R, Rafizadeh F, Esmaeili E, Narimani Zamanabadi M. Saadat Fakhr M, et al. Pain Manag. 2025 Jul;15(7):379-385. doi: 10.1080/17581869.2025.2516415. Epub 2025 Jun 11. Pain Manag. 2025. PMID: 40497407 Free PMC article. Clinical Trial.
This study examines memantine's effectiveness in reducing acute postoperative pain and opioid consumption compared to vitamin C, which served as an active comparator. ...These findings support memantine's potential as a non-opioid adjunct for pain mana …
This study examines memantine's effectiveness in reducing acute postoperative pain and opioid consumption compared to vitamin …
398 results